Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from aTyr Pharma ( (ATYR) ) is now available.
On May 11, 2026, aTyr Pharma reported a regulatory and clinical update on efzofitimod in pulmonary sarcoidosis after receiving minutes from a Type C meeting with the U.S. Food and Drug Administration. The agency’s feedback affirmed forced vital capacity as a direct functional measure and the King’s Sarcoidosis Questionnaire-Lung score as a key symptom measure, guiding aTyr to refine its clinical endpoints and patient selection.
The company plans a new global Phase 3 trial (C-006) in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, after EFZO-FIT previously missed its primary endpoint but showed safety and quality-of-life benefits. The 54-week randomized, double-blind, placebo-controlled study will enroll about 372 patients on stable low-dose corticosteroids or immunosuppressants, use more frequent 5.0 mg/kg dosing every three weeks, and incorporate enhanced safety monitoring to strengthen the benefit-risk profile and regulatory case for efzofitimod.
The most recent analyst rating on (ATYR) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on aTyr Pharma stock, see the ATYR Stock Forecast page.
Spark’s Take on ATYR Stock
According to Spark, TipRanks’ AI Analyst, ATYR is a Neutral.
The score is primarily held down by weak financial performance (very low revenue, widening losses, and heavy cash burn that increases financing/dilution risk). Technicals add some support due to positive momentum, but overbought signals temper that benefit. Valuation remains constrained because losses make P/E uninformative and there is no dividend yield.
To see Spark’s full report on ATYR stock, click here.
More about aTyr Pharma
aTyr Pharma is a biotechnology company focused on advancing tRNA synthetase biology to develop novel protein-based therapeutics. Its lead product candidate, efzofitimod, targets pulmonary sarcoidosis, a major form of interstitial lung disease, with a focus on patients with restrictive lung phenotypes and significant functional impairment.
Average Trading Volume: 1,172,985
Technical Sentiment Signal: Sell
Current Market Cap: $92.79M
For detailed information about ATYR stock, go to TipRanks’ Stock Analysis page.